Surveyor Capital, an investment firm, led a $54m Series C round in OnKure Therapeutics, a precision oncology company, with participation from Deep Track Capital, Acorn Bioventures, Cormorant Asset Management, Perceptive Advisors, Samsara BioCapital, BlackRock, and other undisclosed investors. “We are delighted to be working with our new and existing investors to achieve our vision of developing the next generation of tumor-agnostic, oncology precision medicines.Our team of drug discovery veterans are actively exploring a pipeline of novel oncogene-targeted programs designed to achieve optimal tolerability and efficacy. We look forward to filing our second IND in 2023 and advancing OKI-219 into clinical development early next year,” Tony Piscopio, OnKure Co-Founder, President and CEO.